CLDN2 and gastroesophageal reflux disease: Our global analysis of differential expression of CLDN-2, CLDN-3, and ZO-1 in these well-defined populations suggests that the underlying mechanisms for RS and mucosal changes in patients with active CD are different from those in GERD patients.